沃森生物(300142) - 2016年3月11日投资者关系活动记录表

Group 1: Regulatory Environment - The regulatory environment in the pharmaceutical distribution sector is becoming increasingly stringent, requiring companies to continuously improve their standards [1][2]. - The future of regulation in the biopharmaceutical sector will also see heightened scrutiny, with provincial drug regulatory departments responsible for certifications [1]. Group 2: Strategic Focus - The company aims to enter the monoclonal antibodies and blood products sectors as part of its strategic development plan [3]. - The focus will be on seeking greater development opportunities within these specified fields [3].